EUVIMEDEUVIMED entdecken
CrossrefInfokarte

AL Amyloidosis: Current Treatment and Outcomes

Margaret Locke, Maria Nieto

Advances in Hematology · 2025-01 · 2025 (1)

DOI: 10.1155/ah/7280805 ↗
AbstractBibliografische Angaben

Abstract

Light chain AL amyloidosis is a systemic disorder involving tissue deposition of amyloid fibrils. Often delayed in diagnosis due to nonspecific systemic symptoms, AL amyloidosis must be confirmed on tissue biopsy. Once diagnosis is made, patients can be risk stratified based on the degree of organ involvement and high‐risk cytogenetic features. Currently, the only FDA‐approved first‐line therapy for AL amyloidosis is a combination regimen of daratumumab, cyclophosphamide, bortezomib, and dexamethasone (DaraCyborD) with a goal of achieving a very good partial response (VGPR) after 4‐6 cycles of treatment. Autologous stem cell transplant can be considered in selected cases, although there is no robust evidence of superiority over chemotherapy alone. In the relapsed/refractory setting, numerous promising therapies are still under investigation including venetoclax especially for patients with translocation t (11; 14) and chimeric antigen receptor T‐cell therapy (CART) targeting B‐cell maturation antigen (BCMA). Trial Registration: ClinicalTrials.gov identifier: NCT04270175, NCT05451771, NCT04847453, and NCT05199337

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →